TNBC Foundation Research Grants

The American Association for Cancer Research (AACR) and the Triple Negative Breast Cancer Foundation are pleased to announce a new partnership and grant opportunity. 

The Triple Negative Breast Cancer Foundation announced today that it will support Dr. Karen Cadoo of Memorial Sloan Kettering Cancer Center through the 2014 Conquer Cancer Foundatio

Earlier this year, CCF launched The Campaign to Conquer Cancer, an initiative that is inspiring doctors, survivors, researchers and our incredible supporters to come together to take down cancer.

New research into much-needed treatments for triple negative breast cancer will soon be underway with a new joint research grant from the Samuel Waxman Cancer Research Foundation (SWCRF) and Triple Negative Breast Cancer Foundation (TNBCF). 

Mortality from breast cancer has recently declined, however, the impact of conventional cytotoxic treatment has contributed little to breast cancer survival rates, particularly in advanced stages of this disease. 

The Triple Negative Breast Cancer Foundation (TNBC Foundation) announced that it has selected Mark Pegram, MD to receive its Leslie Simon Breast Cancer Breakthrough Award. The grant will provide $100,000 to investigators in Dr. Pegram’s laboratory who are working to find targets for new therapies for triple negative breast cancer. 

The Triple Negative Breast cancer Foundation, Inc. ("TNBCF") is pleased to award the 2013 Leslie Simon Breast Cancer Research Grant in the amount of $100,000m ("Grant") to Stanford Cancer Institute ("Grantee"), to support research, "theraputic Targeting of Alternative Transition in Triple-Negative Breast Cancer" ("Research"), by Grantee's employees, Mark D. Pegram, M.d> and Toby Ward Ph D. ("Researchers").

The Triple Negative Breast Cancer Foundation announced that it has awarded a research grant to J. Chuck Harrell, PhD and Charles Perou, PhD of the Lineberger Cancer Center of the University of North Carolina. The $100,000 grant will fund Dr. Harrell’s work studying the role of angiogenesis, the ability of tumors to form blood vessels, in promoting the growth and spread of one subtype of triple negative breast cancer (TNBC). 

We are thankful for the support of the Triple Negative Breast Cancer Foundation to further our research efforts into identifying key targets that mediate breast cancer tumor cell endothelial-like morphologies.

Elucidating mechanisms that contribute to breast cancer metastasis, and determining effective options to treat and eradicate cancer cells colonizing vital organs is important as >90% of TNBC deaths are directly attributable to growth of disseminated cells and the formation of metastases. 

Normal cells carry two copies of the BRCA1 gene, one from the individual’s mother and one from their father. In some individuals, one copy of the BRCA1 gene has a mutation that renders it inactive or nonfunctional.  This gene variation is passed from parents to children, and is therefore called a hereditary mutation.

The Triple Negative Breast Cancer Foundation® (TNBCF) awarded two grants, each in the amount of $75,000, to James Ford, MD, associate professor of Medicine and Genetics, Division of Oncology, Stanford University School of Medicine and Shridar Ganesan, MD, Ph.D., assistant professor of Medicine & Pharmacology, Investigator, Cancer Genomics and Molecular Oncology, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey at the fourth annual Triple Negative Breast Cancer Symposium held here today. 

Triple negative breast cancer (TNBC) is an aggressive subtype which represents 15 to 20 percent, or about 30,000, of all new cases of breast cancer in the U.S. each year.